Evidence map›Paper›PMID 30114221›Full record

ArticlePLoS medicine2018

Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.

Mary Dillon, Louisa Flander, Daniel D Buchanan, Finlay A Macrae, Jon D Emery, Ingrid M Winship, Alex Boussioutas, Graham G Giles, John L Hopper, Mark A Jenkins and 1 more

Abstract read
In one paragraph

Article in PLoS medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Circulating cell-free DNA for cancer early detection.Innovation (Cambridge (Mass.)) · 2022
    Review
  3. Evidenced-Based Screening Strategies for a Positive Family History.Gastrointestinal endoscopy clinics of North America · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mary DillonCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
Louisa FlanderCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-0824-9364
Daniel D BuchananCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-2225-6675
Finlay A MacraeColorectal Medicine and Genetics, and the University of Melbourne Department of Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
Jon D EmeryDepartment of General Practice and Centre for Cancer Research, University of Melbourne, Melbourne, Australia.ORCID 0000-0002-5274-6336
Ingrid M WinshipGenomic Medicine and the University of Melbourne Department of Medicine, The Royal Melbourne Hospital, Parkville, Victoria, Australia.ORCID 0000-0001-8535-6003
Alex BoussioutasPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID 0000-0002-8109-6897
Graham G GilesCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0003-4946-9099
John L HopperCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-8567-173X
Mark A JenkinsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0002-8964-6160
Driss Ait OuakrimCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.ORCID 0000-0001-7715-2561

Funding

Data sharing: the Colon Cancer Family Registry CohortU01CA167551 · NCI · UNIVERSITY OF MELBOURNE · PI Daniel David BUCHANAN, Steven Gallinger · 2018 to 2026
$16.8M
Colon Cancer Family Registry CohortUM1CA167551 · NCI · STANFORD UNIVERSITY · PI HAILE, ROBERT WILLIAM, JENKINS, MARK A · 2013 to 2017
$11.3M
NCI NIH HHS U01 CA167551NCI NIH HHS UM1 CA167551
6 · The paper itself

Abstract

backgroundThe Australian National Bowel Cancer Screening Programme (NBCSP) was introduced in 2006. When fully implemented, the programme will invite people aged 50 to 74 to complete an immunochemical faecal occult blood test (iFOBT) every 2 years. METHODS AND

findingsTo investigate colorectal cancer (CRC) screening occurring outside of the NBCSP, we classified participants (n = 2,480) in the Australasian Colorectal Cancer Family Registry (ACCFR) into 3 risk categories (average, moderately increased, and potentially high) based on CRC family history and assessed their screening practices according to national guidelines. We developed a microsimulation to compare hypothetical screening scenarios (70% and 100% uptake) to current participation levels (baseline) and evaluated clinical outcomes and cost for each risk category. The 2 main limitations of this study are as follows: first, the fact that our cost-effectiveness analysis was performed from a third-party payer perspective, which does not include indirect costs and results in overestimated cost-effectiveness ratios, and second, that our natural history model of CRC does not include polyp sojourn time, which determines the rate of cancerous transformation. Screening uptake was low across all family history risk categories (64%-56% reported no screening). For participants at average risk, 18% reported overscreening, while 37% of those in the highest risk categories screened according to guidelines. Higher screening levels would substantially reduce CRC mortality across all risk categories (95 to 305 fewer deaths per 100,000 persons in the 70% scenario versus baseline). For those at average risk, a fully implemented NBCSP represented the most cost-effective approach to prevent CRC deaths (AUS$13,000-16,000 per quality-adjusted life year [QALY]). For those at moderately increased risk, higher adherence to recommended screening was also highly cost-effective (AUS$19,000-24,000 per QALY).

conclusionInvesting in public health strategies to increase adherence to appropriate CRC screening will save lives and deliver high value for money.

Indexed as

AgedAustraliaColorectal NeoplasmsCost-Benefit AnalysisEarly Detection of CancerFemaleGuideline AdherenceHumansImmunochemistryMaleMedical History TakingMiddle AgedModels, EconomicOccult BloodPatient HarmPatient Selection

Identifiers

PMID30114221
PMCPMC6095490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.